Deramciclane

Deramciclane
Deramciclane
Systematic (IUPAC) name
N,N-dimethyl-2-([(1R,4R,6S)-1,7,7-trimethyl-6-phenyl-6-bicyclo[2.2.1]heptanyl]oxy)ethanamine
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 120444-72-6
ATC code None
PubChem CID 119590
UNII O5KFK61E74 YesY
Synonyms Deramciclane
Chemical data
Formula C20H31NO 
Mol. mass 301.466 g/mol
SMILES eMolecules & PubChem
 YesY(what is this?)  (verify)

Deramciclane (EGIS-3886) is a drug which acts as an antagonist at the 5-HT2A receptor,[1] as an inverse agonist at the 5-HT2C receptor,[2] and as a GABA reuptake inhibitor.[3]

In 2003 Orion Pharma of Finland and partner Pharmacia discontinued the development of deramciclane for generalized anxiety disorder, owing to a lack of efficacy in the combined results of the Phase III trials of the agent.

References

  1. ^ Kanerva, H.; Vilkman, H.; Någren, K.; Kilkku, O.; Kuoppamäki, M.; Syvälahti, E.; Hietala, J. (1999). "Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study". Psychopharmacology 145 (1): 76–81. doi:10.1007/s002130051034. PMID 10445375.  edit
  2. ^ Pälvimäki, E. P.; Majasuo, H.; Kuoppamäki, M.; Männistö, P. T.; Syvälahti, E.; Hietala, J. (1998). "Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation". Psychopharmacology 136 (2): 99–104. doi:10.1007/s002130050544. PMID 9551765.  edit
  3. ^ Kovács, I.; Maksay, G.; Simonyi, M. (1989). "Inhibition of high-affinity synaptosomal uptake of gamma-aminobutyric acid by a bicyclo-heptane derivative". Arzneimittel-Forschung 39 (3): 295–297. PMID 2502985.  edit